What is base editing and how does it work in these therapies?
Base editing is a precise form of gene editing that changes one DNA letter to another without cutting the DNA strand, reducing the risk of unintended damage. In the therapies studied, it is used either outside the body (ex vivo) on a patient's own blood stem cells, which are then infused back, or inside the body (in vivo) via a single intravenous injection targeting the liver.
For sickle cell disease, BEAM-101 uses an adenine base editor to disrupt a genetic switch in blood stem cells, reactivating fetal hemoglobin production. In 26 treated patients, this resulted in mean fetal hemoglobin levels above 60% and near-universal expression in red blood cells (99.2% F-cells) by 6 months, exceeding the protective threshold against sickling [1]. For familial hypercholesterolemia, YOLT-101 and VERVE-102 use base editors delivered by lipid nanoparticles to permanently inactivate the PCSK9 gene in liver cells, lowering LDL cholesterol. A single infusion of YOLT-101 at 0.6 mg/kg reduced PCSK9 by 74% and LDL-C by 52% at 24 weeks [5].
Is it safe? What are the main risks?
The safety profile is encouraging but not risk-free. The most serious side effects come from the chemotherapy conditioning needed to prepare the body for new stem cells, not from the base editing itself. In the BEACON study of 26 sickle cell patients, one death occurred due to respiratory failure linked to busulfan conditioning, and no serious adverse events were attributed to BEAM-101 [1]. A systematic review of over 170 patients across gene-editing trials for blood disorders confirmed that all serious adverse events and the one death were due to conditioning, not editing [6].
For in vivo therapies, side effects are milder. In the YOLT-101 trial for high cholesterol, the most common issues were transient infusion reactions (83% of patients) and temporary liver enzyme elevations (50%), with no grade 3 or higher events and no study withdrawals [5]. In the BE-CAR7 trial for T-cell leukemia, all 11 patients achieved remission, but complications included cytokine release syndrome (grades 1-4), cytopenias, and opportunistic infections, with 3 patients experiencing significant virus-related complications after subsequent stem cell transplant [2]. No therapy-related malignancies or confirmed harmful off-target edits have been reported across these studies, though follow-up is still limited (median ~18 months, longest >4 years) [6].
How durable are the effects? Do they last?
The effects appear durable for at least 1-2 years, with the longest follow-up in these studies reaching 18 months for sickle cell and 36 months for leukemia. In the BEACON study, sickle cell patients maintained fetal hemoglobin levels above 60% and had no severe pain crises after engraftment, with durability observed up to 18 months [1]. Peripheral blood editing remained stable at 68-73% from month 3 through month 12 [1].
For high cholesterol, YOLT-101 produced sustained LDL-C reductions of 50% at 4 months and 52% at 24 weeks in the highest dose group [3][5]. Preclinical data in nonhuman primates showed LDL-C lowering lasting over a year after a single dose of a similar base editor [4]. In the leukemia trial, 7 of 11 patients (64%) remained in remission 3 to 36 months after subsequent stem cell transplant [2]. The systematic review noted that transfusion independence in beta-thalassemia patients has been sustained for over 4 years in some cases [6].
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2023 to 2026, 5 from 2024 or later, 4 in Q1 journals, collectively cited 61 times — selected as the most relevant from 8 studies that passed quality screening, drawn from 62 papers retrieved from a database of over 500 million.
Sources used in this answer
Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study
In the BEACON phase 1/2 trial of 26 sickle cell patients, BEAM-101 produced >60% fetal hemoglobin, eliminated severe pain crises post-engraftment, and showed durability up to 18 months; one death was due to busulfan conditioning, not the editing.
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia
In a phase 1 study of 11 patients with relapsed T-cell leukemia, base-edited CAR7 T cells induced complete remission in all, allowing 9 to proceed to stem cell transplant; 7 remained in remission 3-36 months later, though viral reactivations were common.
Base Editing Gene Therapy for Heterozygous Familial Hypercholesterolemia
In an interim analysis of 6 patients with heterozygous familial hypercholesterolemia, a single infusion of YOLT-101 at 0.6 mg/kg reduced PCSK9 by 75.8% and LDL-C by 48.9% at 1 month, with no grade 3+ adverse events.
VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients
This review of the heart-1 trial of VERVE-101 in 10 patients with HeFH reported that sub-therapeutic and therapeutic doses were tested, with LDL-C lowering in nonhuman primates lasting over a year; interim human results were presented at AHA 2023.
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial.
In a phase 1 trial of YOLT-101 for HeFH (6 patients), a single 0.6 mg/kg dose produced sustained PCSK9 reduction of 74.4% and LDL-C reduction of 52.3% at 24 weeks, with no grade 3+ events.
Gene Editing Therapies for Sickle Cell Disease and β-Thalassemia: A Systematic Review of Clinical Outcomes and Safety
This systematic review of over 170 patients across gene-editing trials for sickle cell and beta-thalassemia found that 89-100% achieved transfusion independence (TDT) and ≥97% had no vaso-occlusive crises (SCD); serious adverse events were due to conditioning, not editing.